Jaguar Health Files 8-K: Shareholder Vote & Financials

Ticker: JAGX · Form: 8-K · Filed: 2025-03-13T00:00:00.000Z

Sentiment: neutral

Topics: 8-K, shareholder-vote, financials

Related Tickers: JAGX

TL;DR

Jaguar Health filed an 8-K for shareholder votes and financials - details to come.

AI Summary

On March 13, 2025, Jaguar Health, Inc. filed an 8-K report detailing a submission of matters to a vote of security holders, a Regulation FD disclosure, and financial statements and exhibits. The filing does not contain specific financial figures or details about the matters to be voted on.

Why It Matters

This filing indicates upcoming shareholder decisions and the release of financial information, which could impact the company's strategic direction and investor outlook.

Risk Assessment

Risk Level: low — The filing is procedural and does not contain new material financial information or significant corporate events that would immediately impact risk.

Key Players & Entities

FAQ

What specific matters will be submitted for a vote of Jaguar Health's security holders?

The filing states that matters will be submitted to a vote of security holders, but does not specify what those matters are.

Are there any significant financial updates or results disclosed in this 8-K?

The filing indicates that financial statements and exhibits are included, but the provided text does not detail specific financial results or figures.

What is the purpose of the Regulation FD Disclosure mentioned in the filing?

The filing lists Regulation FD Disclosure as an item, suggesting that the company is ensuring fair disclosure of material information to all investors, but the specific content of the disclosure is not provided in the excerpt.

When was Jaguar Health, Inc. incorporated and in which state?

Jaguar Health, Inc. was incorporated in Delaware.

What is the principal executive office address for Jaguar Health, Inc.?

The principal executive offices are located at 200 Pine Street Suite 400, San Francisco, California, 94104.

From the Filing

0000950170-25-038861.txt : 20250313 0000950170-25-038861.hdr.sgml : 20250313 20250313170009 ACCESSION NUMBER: 0000950170-25-038861 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20250313 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250313 DATE AS OF CHANGE: 20250313 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Jaguar Health, Inc. CENTRAL INDEX KEY: 0001585608 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36714 FILM NUMBER: 25736660 BUSINESS ADDRESS: STREET 1: 200 PINE STREET SUITE 400 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 BUSINESS PHONE: 415-371-8300 MAIL ADDRESS: STREET 1: 200 PINE STREET SUITE 400 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 FORMER COMPANY: FORMER CONFORMED NAME: Jaguar Animal Health, Inc. DATE OF NAME CHANGE: 20130830 8-K 1 jagx-20250313.htm 8-K 8-K false 0001585608 0001585608 2025-03-13 2025-03-13   UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2025     Jaguar Health, Inc. (Exact name of Registrant as Specified in Its Charter)     Delaware 001-36714 46-2956775 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)           200 Pine Street Suite 400   San Francisco , California   94104 (Address of Principal Executive Offices)   (Zip Code)   Registrant’s Telephone Number, Including Area Code: (415) 371-8300     (Former Name or Former Address, if Changed Since Last Report)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, Par Value $0.0001 Per Share   JAGX   The Nasdaq Stock Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐   Item 5.07 Submission of Matters to a Vote of Security Holders. On March 13, 2025, Jaguar Health, Inc. (the “Company”) helda special meeting of stockholders of the Company (the “Special Meeting”). Two proposals were submitted to and approved by the Company’s stockholders, each of which is described in the Company’s definitive proxy statement for the Special Meeting (the “Proxy Statement”), filed with the Securities and Exchange Commission on February 24, 2025. At the Special Meeting, a total of 6,678,281 shares of the Company's common

View on Read The Filing